Palatin Technologies, Inc. (Amex: PTN) requests that journalists and other readers disregard the previous news release regarding the timing of Palatin's financial results and conference call. The timing of these events has not yet been finalized. A follow-up release will be issued early next week.
------
Palatin Technologies to Report Second Quarter, Fiscal Year 2007 Financial Results; Conference Call and Webcast on February 8, 2007
CRANBURY, N.J., Feb. 2 -- Palatin Technologies, Inc. (Amex: PTN) will announce its second quarter, fiscal year 2007 financial results on February 8, 2007 for the period ended December 31, 2006.
The financial results announcement will be followed by a conference call and live audio webcast hosted by Palatin's executive management team when they will discuss the results of operations in greater detail and provide an update on corporate developments.
Schedule for the Financial Results Press Release, Conference Call and
Webcast
- Q2-Fiscal Year 2007 Financial Results
Press Release 2/8/2007 at 7:30 a.m. EST
- Q2-Fiscal Year 2007 Conference Call - Live 2/8/2007 at 10:00 a.m. EST
Domestic Dial-In Number 1-800-811-8845
International Dial-In Number 1-913-981-4905
- Q2-Fiscal Year 2007 Conference Call - Replay 2/8-2/15/2007
Domestic Dial-In Number 1-888-203-1112
International Dial-In Number 1-719-457-0820
Enter Pass Code I.D. # 8388548
- Webcast Live and Replay Access http://www.palatin.com
The webcast and replay can be accessed by logging on to the "Investor
Center-Webcasts" section of Palatin's website at http://www.palatin.com.
About Palatin Technologies, Inc.
Palatin Technologies, Inc. is a biopharmaceutical company focused on discovering and developing targeted, receptor-specific small molecule and peptide therapeutics. The Company's lead product candidate, bremelanotide, is currently in Phase II clinical trials for both male and female sexual dysfunction. The Company's internal research and development capabilities, anchored by its proprietary MIDAS(TM) technology, are fuelling product development. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. To date, the Company has entered into collaborations with AstraZeneca, King Pharmaceuticals and Tyco Healthcare Mallinckrodt. For additional information regarding Palatin, please visit Palatin Technologies' website at http://www.palatin.com.
Forward-looking Statements
Statements about the Company's future expectations, including statements about its development programs, proposed indications for its product candidates, pre-clinical activities, marketing collaborations, and all other statements in this document other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Palatin's actual results may differ materially from those discussed in the forward-looking statements for various reasons, including, but not limited to the Company's ability to fund development of its technology, ability to establish and successfully complete clinical trials and pre- clinical studies and the results of those trials and studies, dependence on its partners for certain development activities, need for regulatory approvals and commercial acceptance of its products, ability to recommence marketing and gain commercial acceptance of NeutroSpec(R), ability to protect its intellectual property, and other factors discussed in the Company's periodic filings with the Securities and Exchange Commission. The Company is not responsible for updating for events that occur after the date of this press release.